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by targeting anti-apoptotic BCL2In this interesting article, Professor Hwang showed an elevated
expression of miR-204 in transfected T24 cells, withmiR-204matu-
rity being conﬁrmed through luciferase reporter assays. The
elevated miR-204 functions to suppress BCL2 mRNA and protein
expression, resulting in increased DNA fragmentation, cleavage of
caspase 3, decreased caspase 3/7 activity, and reduced cell viability.
We look forward to seeing the expression of Bax levels outside the
mitochondria to concretely verify the vicissitudes of antiapoptotic
and apoptotic proteins through the intrinsic apoptosis pathway.1
T24 cells are a high-grade and invasive human urinary bladder
cell line. T24 cells are sensitive to Antrodia camphorate crude ex-
tracts (ACCE), which act as an anti-proliferative and an anti-
metastatic agent, at a concentration of 50 ug/mL.2 The MTT prolif-
eration assay showed that the cell growth and proliferation was
inhibited to 50% of the control when treated with ACCE for 72 h,
at which cell proliferation was suppressed at the rate of
4.4  103 cells/ug per day. Using Western blot analysis, a G2M
phase arrest was conﬁrmed by comparing the expressions of the
cell cycle biomarkers Cdc2 and Cyclin B1. Both the wound scratch
assay and the Transwell motility assay further conﬁrmed that
ACCE is a very effective anti-metastatic against T24 cells. Further-
more, the active form of matrix metalloproteinase-9 (MMP-9)
was found completely suppressed at 72 h post-incubation with
ACCE, as shown by zymography, while the light and electronmicro-
scopic images display cell membrane damages in T24 cells when
treated with ACCE (50 ug/mL).2
Except for the anti-apoptotic and anti-metastatic effects, the up-
per stream ligandereceptor interactions or cell cycle modulation
mechanisms are still concerning because some strategies to
enhance miR-204 overexpression directly or indirectly in vitro are
still ambiguous.3,4
Can activated miR-204 mimic or synthetic miRNAs facilitate
physiological or pathological processes spontaneously in vivo? If
an agent can be shown to function like an effective miRNA mimic,
it will be very promising and reasonable for clinical application.3
In conclusion, the author mentioned that future clinical studies
aiming to elucidate the relationship between miR-204 and anti-
apoptotic genes may provide further insight into the design of
novel molecular therapies for BC, and more importantly, into the
inhibition of the progression of cancer progression and the associ-
ated low overall patient survival. Actually, culture cell lines express
fewermiRNAs than tissues and thusmay not be as real rate-limiting
for disease treatment in vivo.5 Additionally, drug delivery to the
right organs or tissues and choosing the appropriate technology
to modulate the miRNA expression may present general hurdles.5http://dx.doi.org/10.1016/j.urols.2016.05.007
1879-5226/Copyright © 2016, Taiwan Urological Association. Published by Elsevier Ta
creativecommons.org/licenses/by-nc-nd/4.0/).These hurdles will certainly make the road towards miRNA thera-
peutics a very rough one; however, a number of therapeutic pro-
grams with similar initial problems have been proven to be
successful gradually.6
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